NYSE: TMOThermo Fisher Scientific Inc Stock
$548.38+3.60 (+0.66%)
Updated Apr 22, 2024
TMO Price
$548.38
Fair Value Price
N/A
Market Cap
$209.10B
52 Week Low
$415.60
52 Week High
$603.82
P/E
35.33x
P/B
4.47x
P/S
4.78x
PEG
0.68x
Dividend Yield
0.26%
Revenue
$42.86B
Earnings
$6.00B
Gross Margin
39.9%
Operating Margin
17.86%
Profit Margin
14%
Debt to Equity
1.11
Operating Cash Flow
$8B
Beta
0.83
Next Earnings
Apr 24, 2024
Ex-Dividend
N/A
Next Dividend
N/A
TMO Overview
Thermo Fisher Scientific Incorporated offers life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and service worldwide. Its products and services are sold through a direct sales force, customer-service professionals, e-commerce, third-party distributors, and catalogs. It has an alliance with the University of California. Thermo Fisher was incorporated in 1956 and is based in Waltham, MA.
Zen Score
–
Industry Average (28)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how TMO scored across 38 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
TMO ($548.38) is trading above its intrinsic value of $367.71, according to an updated version of Benjamin Graham's Formula from Chapter 11 of "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
TMO is good value based on its earnings relative to its share price (35.33x), compared to the US market average (41x)
P/E vs Market Valuation
TMO is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
There are 35 more TMO due diligence checks available for Premium users.
Be the first to know about important TMO news, forecast changes, insider trades & much more!
TMO News
Valuation
TMO price to earnings (PE)
For valuing profitable companies with steady earnings
Company
35.33x
Industry
36.48x
Market
41x
TMO is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
TMO is good value based... subscribe to Premium to read more.
P/E vs Market Valuation
TMO price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
4.47x
Industry
4.05x
TMO is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
TMO price to earnings growth (PEG)
For valuing profitable companies with growth potential
TMO is good value based... subscribe to Premium to read more.
PEG Value Valuation
TMO's financial health
Profit margin
Revenue
$10.9B
Net Income
$1.6B
Profit Margin
15%
TMO's Earnings (EBIT) of $7.65B... subscribe to Premium to read more.
Interest Coverage Financials
TMO's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$98.7B
Liabilities
$52.0B
Debt to equity
1.11
TMO's short-term assets ($24.59B) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
TMO's long-term liabilities ($37.99B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
TMO's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
TMO's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$3.7B
Investing
-$376.0M
Financing
-$1.4B
TMO's operating cash flow ($8.41B)... subscribe to Premium to read more.
Debt Coverage Financials
TMO vs Diagnostic & Research Stocks
Thermo Fisher Scientific Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.